Segmentation, Major Trends, and Competitive Overview of the Prenatal and Newborn Genetic Testing Market

The prenatal and newborn genetic testing market is poised for significant expansion over the coming years, driven by advances in medical technology and growing demand for early disease detection. With personalized medicine gaining traction and new genetic screening techniques emerging, this market is set to transform prenatal and neonatal healthcare by 2030.

Anticipated Market Size Growth for Prenatal And Newborn Genetic Testing
The market for prenatal and newborn genetic testing is projected to reach $13.65 billion by 2030, growing at a compound annual growth rate (CAGR) of 12.6%. This rapid growth is fueled by the increasing adoption of personalized medicine, heightened demand for early-stage disease detection, expansion of newborn screening programs, rising investments in genomics infrastructure, and the growing use of digital health technologies. Emerging trends shaping the market include wider acceptance of non-invasive prenatal testing, advanced genetic screening panels, the integration of artificial intelligence in genetic risk assessment, expansion of high-throughput sequencing technologies, and an intensified focus on early diagnosis of congenital conditions.

Download a free report of the prenatal and newborn genetic testing market report:
https://www.thebusinessresearchcompany.com/report/prenatal-and-newborn-genetic-testing-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Leading Players Steering the Prenatal and Newborn Genetic Testing Market
Several key companies dominate this market, including F Hoffmann La Roche AG, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton dic*kinson and Company, Quest Diagnostic Incorporated, Agilent Technologies Inc, Illumina Inc, PerkinElmer Genomics, Quidel Corporation, Bio Rad Laboratories Inc, Qiagen NV, Werfen SA, DiaSorin SpA, BGI Group, Natera Inc, Trinity Biotech plc, Meridian Bioscience Inc, Sekisui Diagnostics, Ariosa Diagnostics Inc, AccuBioTech Co Ltd, Sequenom Inc, and Roche Diagnostics International AG.

Collaborative Efforts Enhancing Market Offerings
In February 2024, CooperSurgical Inc., a US-based medical equipment manufacturer, formed a partnership with Fulgent Genetics to broaden its portfolio by incorporating Fulgent's expertise in advanced genetic testing solutions for families using the Cord Blood Registry. Fulgent Genetics Inc., also US-based, specializes in prenatal and newborn genetic testing, and this collaboration aims to enhance genetic testing accessibility and options for consumers.

View the full prenatal and newborn genetic testing market report:
https://www.thebusinessresearchcompany.com/report/prenatal-and-newborn-genetic-testing-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Innovations Accelerating Growth in Prenatal And Newborn Genetic Testing
Major players in the prenatal and newborn genetic testing sector are focusing on developing cutting-edge screening tests that are more accessible and affordable, such as non-invasive prenatal screening tests. Noninvasive prenatal screening (NIPS), also known as noninvasive prenatal testing (NIPT), is a highly advanced and safe technique used during pregnancy to evaluate the risk of fetal chromosomal abnormalities.

Practical Applications of Advanced Screening Tests
For example, in January 2024, Natera, Inc., a US-based genetic testing company, introduced a fetal RhD NIPT designed to assess fetal RhD status, which assists obstetricians in managing care, especially amid nationwide shortages of Rho(D) immune globulin (RhIg). This test is supported by a comprehensive clinical validation study involving over 650 RhD-negative patients with confirmed outcomes, achieving 100% sensitivity and more than 99% specificity. The ability to perform this test early in pregnancy supports timely and improved clinical decision-making.

Segmentation of the Prenatal And Newborn Genetic Testing Market
This report categorizes the prenatal and newborn genetic testing market into several key segments:
1) By Product Type: Consumables and Instruments
2) By Screening Method: Non-Invasive Prenatal Testing, Chronic Villus Sampling, Amniocentesis, Maternal Serum Screening, and Other Screening Methods
3) By Disease Type: Down Syndrome, ket*onuria, Cystic Fibrosis, Sickle Cell Anemia
4) By End User: Hospitals, Maternity and Specialty Clinics, Diagnostic Centers

Further subsegments include:
1) Consumables: Reagents and Assays, Sample Collection Kits, and Test Kits
2) Instruments: Polymerase Chain Reaction (PCR) Machines, Sequencers, and Microarray Analyzers

This detailed segmentation provides a comprehensive understanding of the prenatal and newborn genetic testing landscape and its potential growth avenues through 2030.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.